目的 评价高脂饮食对口服阿雷地平肠溶胶囊后健康中国人体内阿雷地平(AR及其活性代谢产物羟基阿雷地平(AR-M1的药动学(PK、药效学(PD的影响，并评价高脂饮食对该制剂的安全性的影响。方法 采用随机、开放、自身交叉试验设计，12名健康受试者(男女各半分两个阶段分别进行空腹和高脂餐后单次口服AR肠溶胶囊10 mg的PK试验，两次给药间隔7 d。每次给药前及给药后36 h内采集PK血样，采用液相色谱-串联质谱联用法(LC-MS/MS测定健康受试者给药后血浆中AR及AR-M1的浓度。采用DAS2.1.1软件计算AR和AR-M1的主要PK参数(AUC_0-t、AUC_0-∞、ρ_max、t_max、t_1/2、K_e、CL/F、V_d/F等。给药前及给药后36 h内分别测量收缩压(SBP、舒张压(DBP及心率作为药效学指标。整个试验过程中进行全面安全性评估。结果 空腹和高脂餐后单次口服AR肠溶胶囊10 mg 后，AR的AUC_0-t、AUC_0-∞、和t_max有显著性差异(P<0.05。AR-M1的t_max有极显著性差异(P<0.01。其他参数无显著性差异(P>0.05。空腹和高脂餐后单次口服AR，受试者DBP、SBP发生不同程度降低，其中在给药后8 h两组受试者DBP均显著低于基线值(P<0.05，部分受试者心率加快，但无统计学差异；空腹及高脂餐后两组比较，受试者DBP、SBP及心率均无显著性差异。在空腹和高脂餐后给药，男女受试者的主要药动学参数及各药效学指标均无显著性别差异(P>0.05。结论 高脂饮食导致AR的吸收出现延迟现象，吸收程度显著增加；AR-M1的体内生成延迟；血压、心率无显著变化；本研究制剂安全性较好，试验过程无严重不良事件发生。综合考虑，临床应用不需调整用法用量，但应充分考虑病人的饮食习惯，建议空腹给药及清淡饮食。

OBJECTIVE To assess the effects of high-fat meal on the pharmacokinetic(PK and pharmacodynamic(PD properties and safety profile of aranidipine(AR and its active metabolite， hydroxyl-aranidipine(AR-M1， in health Chinese subjects. METHODS One single-dose， open-label， randomized， crossover study of oral aranidipine enteric-coated capsule was conducted in healthy Chinese subjects. Twelve healthy nonsmoking subjects(6 males， 6 females aged from 18 to 45 years were orally administrated aranidipine enteric-coated capsule 10 mg in fasted state. After a washout period of 1 week， the subjects were orally administrated aranidipine enteric-coated capsule 10 mg after high-fat breakfast. Plasma samples were collected previous to the administration as well as at indicated time points after the administration. Concentrations of AR and AR-M1 in plasma were determined by HPLC-MS/MS. PK parameters(AUC_0-t， AUC_0-∞， ρ_max，t_max， t_1/2， K_e， CL/F， V_d/F， etc. of AR and AR-M1 were calculated with DAS 2.1.1. Systolic and diastolic blood pressure(SBP and DBP and heart rate(HR were measured before and at indicated time points after the administration. Safety profile assessment was performed throughout the experiment. RESULTS There was significant increase in AUC_0-t， AUC_0-∞， and t_max for AR given after high-fat meal compared with those in fasted condition(P<0.05. For AR-M1， there was extremely significant increase in t_max(P<0.01 under high-fat meal condition and no significant difference in other parameters(P>0.05. There were no significant changes in BP and HR after the administration in a high-fat meal state compared with that in fasted state. Compared with baseline， there was significant decrease in DBP at 8 h after the administration in both fasted and high-fat meal state (P<0.05. CONCLUSION Oral administration of aranidipine enteric-coated capsule after high-fat meal results in slow absorption and significant increase in bioavailability of AR， as well as significant delay in the generation of AR-M1. There were no significant changes in BP and HR after the administration in either fasted or high-fat meal state. No serious AEs were observed during the experiment， showing the good safety profile of the agent. There is no need to adjust the dosage in clinic application， but light-food and administration in fasted state are recommended.